Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Equity Average (2016 - 2025)

Historic Equity Average for Editas Medicine (EDIT) over the last 10 years, with Q3 2025 value amounting to $16.3 million.

  • Editas Medicine's Equity Average fell 9199.25% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year decrease of 9199.25%. This contributed to the annual value of $241.7 million for FY2024, which is 3189.82% down from last year.
  • Per Editas Medicine's latest filing, its Equity Average stood at $16.3 million for Q3 2025, which was down 9199.25% from $40.8 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Equity Average registered a high of $625.7 million during Q2 2021, and its lowest value of $16.3 million during Q3 2025.
  • Over the past 5 years, Editas Medicine's median Equity Average value was $358.7 million (recorded in 2023), while the average stood at $352.3 million.
  • Per our database at Business Quant, Editas Medicine's Equity Average soared by 10756.01% in 2021 and then crashed by 9199.25% in 2025.
  • Quarter analysis of 5 years shows Editas Medicine's Equity Average stood at $570.2 million in 2021, then crashed by 32.01% to $387.7 million in 2022, then fell by 8.49% to $354.8 million in 2023, then crashed by 56.32% to $155.0 million in 2024, then tumbled by 89.47% to $16.3 million in 2025.
  • Its Equity Average stands at $16.3 million for Q3 2025, versus $40.8 million for Q2 2025 and $98.3 million for Q1 2025.